7.86
前日終値:
$7.83
開ける:
$7.82
24時間の取引高:
1.79M
Relative Volume:
0.60
時価総額:
$1.64B
収益:
$331.41M
当期純損益:
$-226.54M
株価収益率:
-6.661
EPS:
-1.18
ネットキャッシュフロー:
$-97.31M
1週間 パフォーマンス:
-1.50%
1か月 パフォーマンス:
-7.20%
6か月 パフォーマンス:
+3.15%
1年 パフォーマンス:
+54.72%
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
名前
Biocryst Pharmaceuticals Inc
セクター
電話
919-859-1302
住所
4505 EMPEROR BOULEVARD, DURHAM, NC
BCRX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
BCRX
Biocryst Pharmaceuticals Inc
|
7.86 | 1.64B | 331.41M | -226.54M | -97.31M | -1.18 |
![]()
ZTS
Zoetis Inc
|
163.11 | 73.07B | 9.26B | 2.49B | 2.30B | 5.47 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
15.05 | 47.43B | 30.25B | 1.37B | 5.08B | 0.4257 |
![]()
HLN
Haleon Plc Adr
|
10.24 | 45.72B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.08 | 17.28B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
ITCI
Intra Cellular Therapies Inc
|
131.81 | 14.03B | 612.78M | -86.37M | -62.91M | -0.87 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-02-25 | 開始されました | Wedbush | Outperform |
2023-11-20 | 再開されました | JP Morgan | Overweight |
2023-09-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
2023-08-04 | アップグレード | Jefferies | Hold → Buy |
2023-07-13 | アップグレード | BofA Securities | Neutral → Buy |
2023-02-22 | アップグレード | Needham | Hold → Buy |
2022-11-02 | アップグレード | Evercore ISI | In-line → Outperform |
2022-08-05 | ダウングレード | Evercore ISI | Outperform → In-line |
2022-08-05 | ダウングレード | Oppenheimer | Outperform → Perform |
2022-04-18 | ダウングレード | Barclays | Overweight → Equal Weight |
2022-04-11 | ダウングレード | BofA Securities | Buy → Neutral |
2021-12-10 | 開始されました | Oppenheimer | Outperform |
2021-08-06 | ダウングレード | Jefferies | Buy → Hold |
2021-08-03 | 開始されました | Cantor Fitzgerald | Overweight |
2021-03-01 | 開始されました | Cowen | Outperform |
2020-09-29 | 再開されました | JP Morgan | Overweight |
2020-06-17 | 開始されました | BTIG Research | Neutral |
2020-05-05 | アップグレード | Barclays | Equal Weight → Overweight |
2019-11-15 | アップグレード | BofA/Merrill | Neutral → Buy |
2019-05-24 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
2018-11-16 | 再開されました | Piper Jaffray | Overweight |
2018-08-08 | 再開されました | JP Morgan | Overweight |
2018-07-17 | アップグレード | BofA/Merrill | Underperform → Neutral |
2018-06-22 | 開始されました | Seaport Global Securities | Neutral |
2018-01-02 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
2017-12-20 | 開始されました | Barclays | Equal Weight |
2017-09-15 | 開始されました | RBC Capital Mkts | Sector Perform |
2017-09-06 | アップグレード | JP Morgan | Neutral → Overweight |
2017-09-06 | アップグレード | Jefferies | Hold → Buy |
2017-02-16 | 開始されました | Ladenburg Thalmann | Buy |
2016-08-12 | アップグレード | Piper Jaffray | Neutral → Overweight |
2016-08-04 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
2016-02-09 | 繰り返されました | FBR Capital | Outperform |
2016-02-09 | ダウングレード | JP Morgan | Overweight → Neutral |
2016-02-09 | ダウングレード | Needham | Buy → Hold |
すべてを表示
Biocryst Pharmaceuticals Inc (BCRX) 最新ニュース
BioCryst's Booming HAE Drug Sales Set The Stage For A Strong 2025Will The Stock Follow? - RTTNews
North Carolina biotech sues to block copies of $400M drug - The Business Journals
Institutional investors control 75% of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and were rewarded last week after stock increased 4.9% - Yahoo Finance
Groundbreaking Step in Battling Angioedema at UC San Diego - University of California San Diego
The 4.9% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 295% - Simply Wall St
(BCRX) Technical Data - Stock Traders Daily
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
25,583 Shares in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Bought by Proficio Capital Partners LLC - Defense World
BioCryst’s SWOT analysis: orladeyo success fuels growth amid competition By Investing.com - Investing.com South Africa
BioCryst’s SWOT analysis: orladeyo success fuels growth amid competition - Investing.com
BioCryst at Barclays Conference: Strategic Growth and Pipeline Focus By Investing.com - Investing.com Canada
BioCryst sues to protect ORLADEYO patents By Investing.com - Investing.com Canada
BioCryst Sues Hetero to Block Copies of Drug Worth $386 Million - Bloomberg Law
BioCryst takes legal action to defend rare genetic drug patent; shares fall - TradingView
BioCryst sues to protect ORLADEYO patents - Investing.com India
Biocryst PharmaceuticalsOn March 10, Files Patent Infringement Lawsuit Against Annora And Other Co's - Marketscreener.com
Insider Buying: Chief R&D Officer Helen Thackray Acquires 30,000 Shares of BioCryst Pharmaceuticals Inc (BCRX) - GuruFocus.com
Principal Financial Group Inc. Sells 393,607 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
Orladeyo safely prevents swelling attacks in young children with HAE - Angioedema News Today
BioCryst at TD Cowen Conference: Strategic Growth Insights - Investing.com
BioCryst at TD Cowen Conference: Strategic Growth Insights By Investing.com - Investing.com UK
BioCryst Pharmaceuticals Inc (BCRX) Announces Grant of Restricted Stock Units to New Employees - GuruFocus.com
BioCryst reports inducement grants under Nasdaq listing rule - TipRanks
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BioCryst's Latest Employee Stock Awards: Key Details on 65,900 RSU Grants - StockTitan
BioCryst CFO resigns, search for successor begins By Investing.com - Investing.com Australia
CFO Anthony Doyle resigns at Biocryst - BioCentury
BioCryst CFO resigns, search for successor begins - Investing.com India
BioCryst CFO Anthony Doyle Resigns Effective April 2025 - TipRanks
Where are the Opportunities in (BCRX) - Stock Traders Daily
Rhumbline Advisers Has $2.33 Million Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
BioCryst stock holds $18 target, JMP bullish on trial results By Investing.com - Investing.com Canada
Is BioCryst Pharmaceuticals, Inc. (BCRX) the Best Small-Cap Stock to Buy Now? - MSN
Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher - MSN
10 Best Small-Cap Stocks to Buy Now - Insider Monkey
BioCryst Pharmaceuticals' (BCRX) "Outperform" Rating Reaffirmed at Royal Bank of Canada - MarketBeat
Wedbush Initiates Coverage on BioCryst Pharmaceuticals (NASDAQ:BCRX) - MarketBeat
HC Wainwright Reiterates Buy Rating for BioCryst Pharmaceuticals (NASDAQ:BCRX) - MarketBeat
Analysts Set Expectations for BCRX Q1 Earnings - Defense World
BioCryst Pharmaceuticals (NASDAQ:BCRX) Issues Earnings Results - MarketBeat
BioCryst stock soars to 52-week high, touches $9.02 - MSN
BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down Following Weak Earnings - MarketBeat
Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know - MSN
Biocryst Pharmaceuticals Inc (BCRX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):